Core Insights - The latest research results of FIC innovative small molecule CKBA from Tianen Kang have been published in the prestigious journal Nature Aging, providing new theoretical basis and drug development direction for Alzheimer's disease treatment [1] Company Developments - Tianen Kang is advancing CKBA in clinical trials for vitiligo (Phase III) and rosacea (Phase II/III), while accelerating the research and development process for Alzheimer's disease treatment, potentially offering new hope for millions of patients globally [1] Research Findings - The study reveals a novel mechanism linking lipid metabolism disorder and brain immune activation, identifying the "lipid-inflammation" axis and the targeted value of the new target MFE-2 [1] - A complete pathogenic pathway has been constructed: "MFE-2 functional deficiency → lipid metabolism disorder → inflammatory activation → neurodegenerative changes," marking a significant breakthrough in Alzheimer's disease intervention in China [1]
泰恩康：CKBA治疗阿尔茨海默症研究登顶刊 揭示全新致病机制